IDEXX Laboratories (IDXX) – Investment Analysts’ Recent Ratings Changes

IDEXX Laboratories (NASDAQ: IDXX) recently received a number of ratings updates from brokerages and research firms:

• 11/4/2025 – IDEXX Laboratories had its price target raised by analysts at Morgan Stanley from $765.00 to $805.00. They now have an “overweight” rating on the stock.
• 11/4/2025 – IDEXX Laboratories had its price target raised by analysts at UBS Group AG from $710.00 to $750.00. They now have a “neutral” rating on the stock.
• 11/4/2025 – IDEXX Laboratories had its price target raised by analysts at BTIG Research from $785.00 to $830.00. They now have a “buy” rating on the stock.
• 11/4/2025 – IDEXX Laboratories had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $830.00 price target on the stock.
• 11/4/2025 – IDEXX Laboratories had its price target raised by analysts at JPMorgan Chase & Co. from $675.00 to $775.00. They now have an “overweight” rating on the stock.
• 11/3/2025 – IDEXX Laboratories was given a new $785.00 price target on by analysts at Leerink Partners.
• 11/3/2025 – IDEXX Laboratories was given a new $775.00 price target on by analysts at Stifel Nicolaus.
• 10/31/2025 – IDEXX Laboratories was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $700.00 price target on the stock, up previously from $640.00.
• 10/8/2025 – IDEXX Laboratories had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/1/2025 – IDEXX Laboratories is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $720.00 price target on the stock.
• 10/1/2025 – IDEXX Laboratories is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $720.00 price target on the stock.
• 9/28/2025 – IDEXX Laboratories was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 9/27/2025 – IDEXX Laboratories had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/20/2025 – IDEXX Laboratories was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.

Insider Activity

In other news, Director M Anne Szostak sold 2,187 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the sale, the director owned 262 shares of the company’s stock, valued at $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael G. Erickson sold 406 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president owned 11,287 shares of the company’s stock, valued at $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 9,243 shares of company stock valued at $6,018,650 over the last ninety days. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.